Enterobacteriaceae

Kemin Industries Celebrates 20 Years of CLOSTAT™ and Probiotic Excellence in Intestinal Health for Production Animals

Retrieved on: 
Wednesday, April 17, 2024
Kemin Industries, Poultry, Clostridium perfringens, Escherichia coli, Conference, Friends, Salmonella, Livestock, Bacillus, Enterobacteriaceae, Quality of life, Growth

MANILA, Philippines, April 16, 2024 /PRNewswire/ -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, is celebrating two decades of CLOSTAT™, its flagship probiotic product for managing intestinal health in poultry and livestock. To commemorate the milestone, the Kemin Animal Nutrition and Health – Asia Pacific business unit hosted an anniversary dinner on Tuesday, April 16, in Manila, Philippines. The event coincided with the 8th International Conference on Poultry Intestinal Health (ICPIH), also held in the country's capital city, on April 17–19.

Key Points: 
  • The event coincided with the 8th International Conference on Poultry Intestinal Health (ICPIH), also held in the country's capital city, on April 17–19.
  • Kemin's probiotic solution has pioneered the promotion of healthy microbiome to drive intestinal resilience, manage gut health challenges, and improve animal productivity.
  • "We are extremely proud of the impact of CLOSTAT over the past 20 years," said Dr. Chris Nelson, President and CEO, Kemin Industries.
  • Click here to see where CLOSTAT and ENTEROSURE are available in the Asia-Pacific region and to learn more about their intestinal health benefits.

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

Retrieved on: 
Monday, October 16, 2023
Infection, Klebsiella pneumoniae, Hospital, Disease, Food, Gram-negative bacteria, Campaign, Fungal infection, HAI, Trial of the century, Bacteria, Acinetobacter baumannii, Escherichia coli, Intellectual property, IND, CDC, Mortality, Enterobacter cloacae, VABP, State, Pseudomonas aeruginosa, Patient, FDA, XDR, MDR, Peptide, Clinical trial, Pneumonia, Gram, ICU, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Enterobacter, Bronchopneumonia, Pharmaceutical industry, MD, Enterobacteriaceae

“We are very pleased with the FDA’s clearance of our IND application for CF-370.

Key Points: 
  • “We are very pleased with the FDA’s clearance of our IND application for CF-370.
  • HABP/VABP occurs in patients in hospitals or other health care facilities and can be caused by a variety of bacteria.
  • P. aeruginosa, Acinetobacter species, Klebsiella species, E. coli and Enterobacter species are the most commonly implicated Gram-negative pathogens in HABP/VABP infections.
  • The HAI Progress Report includes data from 3,917 facilities reporting to the National Healthcare Safety Network covering 36.3 million hospital admissions.

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

Retrieved on: 
Monday, September 18, 2023
State, Human, XDR, Probability, Gram, HAI, Infection, Drug discovery, Clinical trial, Bacterial pneumonia, Pharmacokinetics, Hope, Escherichia coli, Prognosis, Consultant, CDC, Pseudomonas aeruginosa, Death, MDR, VABP, Hospital, Patient, Disease, Toxicology, Fungal infection, Bronchopneumonia, Mortality, Bacteria, Campaign, ICU, FDA, Pharmacology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Enterobacter cloacae, Food, Peptide, Pharmaceutical industry, Enterobacteriaceae, MD

The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Key Points: 
  • The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
  • New therapies to treat these infections are critically important to meet patient needs, particularly because of increasing antimicrobial resistance.
  • HABP/VABP occurs in patients in hospitals or other health care facilities and can be caused by a variety of bacteria.
  • Additionally, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials.

PathogenDx Enables Labs to Meet Cannabis Testing Regulations in Every State With Launch of Rapid Bacterial Semi-Quantification Four-in-One Test

Retrieved on: 
Tuesday, August 15, 2023
Enterobacteriaceae, 3D, Temperature, IPC, D3, 3D XPoint, Health, ROI, Family, PCR, Safety, Software, Vaccine

Company Now Offers Cannabis' Most Comprehensive and Adaptable Microbial Testing Platform

Key Points: 
  • Scottsdale, Arizona--(Newsfile Corp. - August 15, 2023) - PathogenDx , a leader in next-generation microarray technology for better health and safety, announced the launch of QuantX Bacterial , a new rapid bacterial semi-quantification four-in-one assay that enables cannabis testing labs to efficiently meet any state's microbial testing regulations.
  • PathogenDx has also added the option of manual or automated sample prep to its cannabis testing platform, which includes Quantx Bacterial, Detectx Combined and Quantx Fungal.
  • For cannabis testing labs' ease, it offers the capability of semi-quantifying four bacterial broad class indicators plus species specific detection within each broad class.
  • With PathogenDx's cannabis testing platform, everything works together seamlessly – from testing, to software, to reporting."

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances

Retrieved on: 
Saturday, June 10, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Antibiotics, Vaccine, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • Recent discovery of plasmid-mediated transferable colistin resistance genes have shown the ease with which resistance can spread in bacterial populations.
  • No cross-resistance with standard of care antibiotics was observed and the demonstrated Enterobacteriaceae-specificity versus broad-spectrum activity supports continued development for this class of antibiotics for the potential management and treatment of antimicrobial resistant pathogens.

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carba

Retrieved on: 
Wednesday, June 7, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Vaccine, Antibiotics, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • Antimicrobial resistance (AMR) has emerged as a significant threat for both patients and healthcare systems.
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • The compounds showed potent in vivo efficacy, especially in lung infection models as well as a promising in vitro and in vivo safety profile.

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Infectious Diseases, Health, Clinical Trials, Oncology, Myelodysplastic syndrome, Graft-versus-host disease, VRE, Therapy, Doctor of Philosophy, Gastrointestinal tract, Cohort, Head, Infection, Malignancy, Immune tolerance, David Berry (inventor), Streptococcaceae, Enterococcus-1 RNA motif, AMR, Hematopoietic stem cell transplantation, HSCT, Acute myeloid leukemia, Bone marrow, Incidence, Carbapenem-resistant enterobacteriaceae, Patient, Division, Risk, ESKAPE, Memorial Sloan Kettering Cancer Center, Cancer, MSK, Mortality, Bacteria, Haematopoietic system, GI, CRE, Conference, Bloodstream infections, Safety, Vaccine, Pharmaceutical industry, Antibiotics, Enterobacteriaceae, Staphylococcaceae, Enterococcaceae

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported initial clinical data about SER-155.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported initial clinical data about SER-155.
  • Enrollment in the placebo-controlled Cohort 2 portion of the study is ongoing and topline results are anticipated in mid-2024.
  • The SER-155 Phase 1b study includes two cohorts, with Cohort 1 designed to assess safety and drug pharmacology, including the engraftment of drug bacteria in the gastrointestinal tract.
  • ET to discuss Q1 2023 financial results and provide a business update, including a discussion of new SER-155 study results.

Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, May 9, 2023
Health, FDA, Stem Cells, Other Health, Other Science, Research, Science, VRE, The New England Journal of Medicine, CDI, Cohort, Chills, Streptococcaceae, AMR, JAMA Network Open, Patient, Investment, Risk, R, Fatigue, Graft-versus-host disease, Abdominal distension, Therapy, Diarrhea, Food, Constipation, Food and Drug Administration Amendments Act of 2007, Kinetics, GI, Cirrhosis, Conference, Safety, Oak Tree, David Berry (inventor), Enterococcus-1 RNA motif, P&L, Carbapenem-resistant enterobacteriaceae, UC, Variometer, Spore, Infection, Oaktree Capital Management, Gastrointestinal tract, ESKAPE, CRE, Recurrence, Bloodstream infections, Antibiotics, Pharmaceutical industry, Vaccine, Medicinal plants, Medical device, Health care, Enterococcaceae, Enterobacteriaceae, Staphylococcaceae

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates.
  • Included in the first quarter 2023 R&D expenses of $44 million is approximately $16 million of commercial manufacturing costs for VOWST.
  • Seres ended the first quarter of 2023 with $106.5 million in cash, cash equivalents and investments as compared with $181.3 million at the end of 2022.
  • To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch .

T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices

Retrieved on: 
Wednesday, April 5, 2023
University of Pittsburgh Epidemiology Data Center, Enterobacteriaceae, Hospice and palliative medicine, Medicine, Differential diagnoses of depression, Candidiasis, XDR, University, MICU, Infection, Septic shock, Associate, Patient, Risk, NIH, Pharmaceutical industry

LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the availability of a new webinar and white paper highlighting the T2Candida® Panel clinical data and best practices from real world use within Medical Intensive Care Units (MICU).

Key Points: 
  • LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the availability of a new webinar and white paper highlighting the T2Candida® Panel clinical data and best practices from real world use within Medical Intensive Care Units (MICU).
  • “In a setting where time and accuracy are vital, the T2Candida Panel can be incorporated into patient management and stewardship.
  • The T2 Medical Affairs team also released a new supplementary white paper that synthesizes the T2Candida Panel hospital user experiences.
  • The white paper includes patient selection criteria, treatment algorithms, patient outcomes, and patient case studies from the T2Candida Panel hospital users.

AstraGin®, Developed by NuLiv Science, Demonstrates Improvements in Gut Health in Human Clinical Trial

Retrieved on: 
Monday, April 3, 2023
Breakfast, Enterobacteriaceae, Ghrelin, Growth, Clinical trial, UC, Patient, Probiotic, AUC, Dietary supplement, Faecalibacterium, Prevotella, Bifidobacterium

The results demonstrated that AstraGin® effectively improved intestinal barrier integrity, increased the population of beneficial bacteria, and mitigated the growth of harmful bacteria in the gut.

Key Points: 
  • The results demonstrated that AstraGin® effectively improved intestinal barrier integrity, increased the population of beneficial bacteria, and mitigated the growth of harmful bacteria in the gut.
  • Furthermore, the trial showed a positive impact on ghrelin, an appetite hormone often affected by gut health challenges.
  • Richard Wang, CEO at NuLiv Science noted, "The professors behind AstraGin® explored multiple pathways on how AstraGin® supports bioavailability.
  • For more information about AstraGin® and the clinical trial, please visit www.nulivscience.com or contact the company's marketing director, Josh Beaty, at [email protected] .